{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T17:15:37Z","timestamp":1790702137326,"version":"4.1.0"},"reference-count":20,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T00:00:00Z","timestamp":1736208000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.mdpi.com"],"crossmark-restriction":true},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Objectives: Parenteral drug products manufactured under GMP conditions should be visually inspected for defects and particulate contamination by trained and qualified personnel. Although personnel qualification is required, no practical protocols or formal guidelines are available for the development of qualification test sets (QTSs) used for qualification procedures. The current practice is to either procure a standardized QTS from a commercial supplier or amass sufficient manufacturing rejects during visual inspection procedures to compile in-house QTSs. However, both strategies inherently possess disadvantages and limitations. The objective of this study was to develop a manufacturing protocol for an optimal and adaptable QTS for training and qualification procedures. Methods: We combined the results of a literature search, survey of five Dutch hospital pharmacy compounding facilities, semi-structured personnel interviews, and extensive pre-GMP formulation studies to develop an optimal and adaptable QTS manufacturing protocol. Results: The literature search did not identify a manufacturing protocol for an optimal and adaptable QTS, but did identify specifications and requirements for optimal QTSs. The survey among hospital pharmacy compounding facilities revealed considerable variability in the qualification procedures and used QTSs. Semi-structured personnel interviews and pre-GMP formulation studies demonstrated that defects encountered during routine productions could be realistically simulated with pharmaceutical-grade excipients. As a proof-of-concept, we manufactured two different QTSs under GMP conditions and assessed these for formal GMP training and qualification purposes, which were considered a significant improvement compared to using manufacturing rejects. Conclusions: To the best of our knowledge, this is the first study presenting these data and our adaptable protocol, which is provided in the Supplemental Materials, may aid compounding facilities in the standardization, training, and qualification of personnel involved in visual inspection procedures.<\/jats:p>","DOI":"10.3390\/pharmaceutics17010074","type":"journal-article","created":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T07:42:19Z","timestamp":1736235739000},"page":"74","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Development of an Adaptable Qualification Test Set for Personnel Involved in Visual Inspection Procedures of Parenteral Drug Products Manufactured Under Good Manufacturing Practice Conditions in Hospital Pharmacy Compounding Facilities"],"prefix":"10.3390","volume":"17","author":[{"given":"Tessa","family":"van den Born-Bondt","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen (UMCG), 9713 GZ Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harmen P. S.","family":"Huizinga","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen (UMCG), 9713 GZ Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koen R.","family":"Kappert","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen (UMCG), 9713 GZ Groningen, The Netherlands"},{"name":"Department of Pharmaceutical Technology and Biopharmacy, Groningen Research Institute of Pharmacy (GRIP), University of Groningen, Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans H.","family":"Westra","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen (UMCG), 9713 GZ Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacoba","family":"van Zanten","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen (UMCG), 9713 GZ Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9450-5880","authenticated-orcid":false,"given":"Herman J.","family":"Woerdenbag","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Technology and Biopharmacy, Groningen Research Institute of Pharmacy (GRIP), University of Groningen, Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacoba M.","family":"Maurer","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen (UMCG), 9713 GZ Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8672-391X","authenticated-orcid":false,"given":"Bahez","family":"Gareb","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen (UMCG), 9713 GZ Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,1,7]]},"reference":[{"key":"ref_1","unstructured":"(2024, November 04). EU GMP Annex 1. Available online: https:\/\/health.ec.europa.eu\/system\/files\/2022-08\/20220825_gmp-an1_en_0.pdf."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Le Brun, P., Crauste-Manciet, S., Kr\u00e4mer, I., Smith, J., and Woerdenbag, H. (2023). Practical Pharmaceutics, Springer Nature Switzerland AG. [2nd ed.].","DOI":"10.1007\/978-3-031-20298-8"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1136\/ejhpharm-2022-003633","article-title":"Testing of Parenteral Drug Products for Visible Particles: Comparison of the Ph. Eur. Method with an Alternative Method Using Polarised Light","volume":"31","author":"Borgonje","year":"2024","journal-title":"Eur. J. Hosp. Pharm."},{"key":"ref_4","unstructured":"US Pharmaceutical Convention (2023). United States Pharmacopeia. Monograph \u23291787\u232a Measurement of Subvisible Particulate Matter in Therapeutic Protein Injections, USP-NF."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"134","DOI":"10.5731\/pdajpst.2015.006064","article-title":"Semi-Quantitative Analysis of Inherent Visible Particles for Biopharmaceutical Products","volume":"70","author":"Cash","year":"2016","journal-title":"PDA J. Pharm. Sci. Technol."},{"key":"ref_6","unstructured":"European Directorate for the Quality of Medicines & HealthCare (2024). Particulate Contamination: Visible Particles. European Pharmacopoeia (Ph.Eur.), EDQM Council of Europe. [11.5 ed.]. Available online: https:\/\/pheur.edqm.eu\/home."},{"key":"ref_7","unstructured":"US Pharmaceutical Convention (2023). United States Pharmacopeia. Monograph  <1790> Visual Inspections of Injections, NF-USP."},{"key":"ref_8","unstructured":"(2024, November 04). FDA Inspection of Injectable Products for Visible Particulates Guidance for Industry DRAFT GUIDANCE. Available online: https:\/\/www-fda-gov.proxy-ub.rug.nl\/media\/154868\/download."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"273","DOI":"10.5731\/pdajpst.2012.00862","article-title":"Considerations for Design and Use of Container Challenge Sets for Qualification and Validation of Visible Particulate Inspection","volume":"66","author":"Melchore","year":"2012","journal-title":"PDA J. Pharm. Sci. Technol."},{"key":"ref_10","unstructured":"British Pharmacopoeia SC I N (2024). Particulate Contamination. BP 2024 (Ph. Eur. 11.5 Update), The Stationery Office Ltd. (TSO). Medicines & Healthcare producs Regulator Agency."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.ejpb.2016.05.008","article-title":"Development, Preclinical Safety, Formulation, and Stability of Clinical Grade Bevacizumab-800CW, a New near Infrared Fluorescent Imaging Agent for First in Human Use","volume":"104","author":"Linssen","year":"2016","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_12","unstructured":"Parental Drug Association (PDA), and Shabushnig, J.G. (2024, November 04). Visual Inspection of Injectable Products: More than Sorting Good from Bad\u2026. Available online: https:\/\/www.scribd.com\/document\/711615516\/PDA-Visual-Inspection-of-Injectable-Products."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1002\/jps.20079","article-title":"Challenges in the Development of High Protein Concentration Formulations","volume":"93","author":"Shire","year":"2004","journal-title":"J. Pharm. Sci."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1208\/ps050210","article-title":"Mechanisms of Aggregate Formation and Carbohydrate Excipient Stabilization of Lyophilized Humanized Monoclonal Antibody Formulations","volume":"5","author":"Andya","year":"2003","journal-title":"AAPS PharmSci"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1208\/s12249-010-9577-7","article-title":"Sound Practices for Consistent Human Visual Inspection","volume":"12","author":"Melchore","year":"2011","journal-title":"AAPS Pharmscitech"},{"key":"ref_16","first-page":"265","article-title":"Standard Particulate Sets for Visual Inspection Systems: Their Preparation, Evaluation, and Applications","volume":"40","author":"Borchert","year":"1986","journal-title":"Parenter. Sci. Technol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"7362","DOI":"10.1021\/acs.iecr.6b01573","article-title":"Gas-Phase Surface Engineering of Polystyrene Beads Used to Challenge Automated Particle Inspection Systems","volume":"55","author":"Marion","year":"2016","journal-title":"Ind. Eng. Chem. Res."},{"key":"ref_18","unstructured":"(2024, March 07). IPS-Group A\/S Sontara\u00ae Micropure AP. Available online: https:\/\/ips-group.dk\/product\/sontara-micropure-ap\/."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Linssen, M.D., Hooghiemstra, W.T.R., Jorritsma-Smit, A., Allersma, D.P., Dijkstra, G., and Nagengast, W.B. (2021). Development and Characterisation of Antibody-Based Optical Imaging Probes for Inflammatory Bowel Disease. Pharmaceuticals, 14.","DOI":"10.3390\/ph14090922"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Oosting, L.T., Franke, K., Martin, M.V., Kloosterman, W.P., Jamieson, J.A., Glenn, L.A., de Jager, M.W., van Zanten, J., Allersma, D.P., and Gareb, B. (2022). Development of a Personalized Tumor Neoantigen Based Vaccine Formulation (FRAME-001) for Use in a Phase II Trial for the Treatment of Advanced Non-Small Cell Lung Cancer. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14071515"}],"updated-by":[{"DOI":"10.3390\/pharmaceutics17050564","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T00:00:00Z","timestamp":1736208000000}}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/17\/1\/74\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,3]],"date-time":"2025-08-03T14:42:45Z","timestamp":1754232165000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/17\/1\/74"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,7]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1]]}},"alternative-id":["pharmaceutics17010074"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics17010074","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,7]]}}}